Your browser doesn't support javascript.
loading
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance.
Casolino, Raffaella; Beer, Philip A; Chakravarty, Debyani; Davis, Melissa B; Malapelle, Umberto; Mazzarella, Luca; Normanno, Nicola; Pauli, Chantal; Subbiah, Vivek; Turnbull, Clare; Westphalen, C Benedikt; Biankin, Andrew V.
Afiliação
  • Casolino R; Wolfson Wohl Cancer Research Center, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Beer PA; Wolfson Wohl Cancer Research Center, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Chakravarty D; Hull York Medical School, York, UK.
  • Davis MB; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Malapelle U; Department of Surgery, Weill Cornell Medicine, New York City, New York, USA.
  • Mazzarella L; Department of Public Health, University of Naples Federico II, Naples, Italy.
  • Normanno N; Laboratory of Translational Oncology and Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors IEO European Institute of Oncology, IRCCS, Milan, Italy.
  • Pauli C; Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS "Fondazione G. Pascale", Naples, Italy.
  • Subbiah V; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Turnbull C; Sarah Cannon Research Institute, Nashville, Tennessee, USA.
  • Westphalen CB; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Biankin AV; National Cancer Registration and Analysis Service, National Health Service (NHS) England, London, UK.
CA Cancer J Clin ; 74(3): 264-285, 2024.
Article em En | MEDLINE | ID: mdl-38174605
ABSTRACT
The last decade has seen rapid progress in the use of genomic tests, including gene panels, whole-exome sequencing, and whole-genome sequencing, in research and clinical cancer care. These advances have created expansive opportunities to characterize the molecular attributes of cancer, revealing a subset of cancer-associated aberrations called driver mutations. The identification of these driver mutations can unearth vulnerabilities of cancer cells to targeted therapeutics, which has led to the development and approval of novel diagnostics and personalized interventions in various malignancies. The applications of this modern approach, often referred to as precision oncology or precision cancer medicine, are already becoming a staple in cancer care and will expand exponentially over the coming years. Although genomic tests can lead to better outcomes by informing cancer risk, prognosis, and therapeutic selection, they remain underutilized in routine cancer care. A contributing factor is a lack of understanding of their clinical utility and the difficulty of results interpretation by the broad oncology community. Practical guidelines on how to interpret and integrate genomic information in the clinical setting, addressed to clinicians without expertise in cancer genomics, are currently limited. Building upon the genomic foundations of cancer and the concept of precision oncology, the authors have developed practical guidance to aid the interpretation of genomic test results that help inform clinical decision making for patients with cancer. They also discuss the challenges that prevent the wider implementation of precision oncology.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes Genéticos / Genômica / Medicina de Precisão / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: CA Cancer J Clin Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes Genéticos / Genômica / Medicina de Precisão / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: CA Cancer J Clin Ano de publicação: 2024 Tipo de documento: Article